JDTic

JDTic ((3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide) is the first potent, kappa-opioid receptor (KOR) selective antagonist not derived from a morphinan or opiate scaffold and is among the most thoroughly characterized selective KOR ligands in the preclinical pharmacology literature. Developed by F. Ivy Carroll and colleagues at Research Triangle Institute (RTI International) through systematic optimization of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine pharmacophore, JDTic exhibits subnanomolar binding affinity at the human KOR (Ki approximately 0.32 nM; functional IC50 approximately 0.02 nM in GTPgammaS assays) with greater than 300-fold selectivity over the mu-opioid receptor (MOR) and greater than 4900-fold selectivity over the delta-opioid receptor (DOR) [1, 2]. The compound is devoid of agonist activity at canonical and non-canonical opioid receptor signaling pathways and produces antagonism that persists for two to four weeks after a single parenteral dose in rodent models, a duration attributable not to pharmacokinetic persistence but to ligand-directed activation of c-Jun N-terminal kinase 1 (JNK1), which produces sustained receptor inactivation through a mechanism distinct from simple competitive blockade [3, 4].

The crystal structure of the human KOR in complex with JDTic, resolved at 2.9 angstrom, revealed the molecular determinants of subtype selectivity and confirmed that JDTic achieves its exceptional KOR preference through "message" interactions within the orthosteric binding pocket rather than through the classical "address" motif employed by morphinan antagonists such as norbinaltorphimine [5]. The structure identified key selectivity-conferring residues (Val108, Val118, Tyr312, Ile294) that distinguish the KOR binding pocket from the MOR and DOR and has served as a foundational template for computational studies of opioid receptor selectivity and for structure-based design of next-generation KOR antagonists.

In preclinical pharmacology, JDTic has demonstrated robust efficacy across a broad range of stress-related behavioral models. The compound selectively blocks stress-induced reinstatement of cocaine seeking without affecting cocaine-primed reinstatement, attenuates alcohol self-administration and cue-induced reinstatement of alcohol seeking, reverses withdrawal-associated anxiety, produces antidepressant-like effects in the forced swim test, and attenuates both physical and affective signs of nicotine withdrawal [6, 7, 8, 9]. These findings, replicated across multiple laboratories and species, provided the scientific rationale for advancing JDTic into human clinical trials as a potential treatment for cocaine use disorder and stress-related psychiatric conditions.

A Phase 1 double-blind, placebo-controlled, single-ascending-dose trial in 12 healthy adult males was conducted to evaluate safety, tolerability, and pharmacokinetics [10, 11]. At the initial dose of 1 mg oral, plasma JDTic concentrations were below the lower limit of quantitation (0.1 nM) in all subjects, precluding pharmacokinetic characterization. Two of the six JDTic-treated subjects (33 percent) experienced asymptomatic episodes of nonsustained ventricular tachycardia (NSVT) at approximately 11.5 and 13.5 hours postdose, compared to zero of six placebo subjects. The Data Safety Monitoring Board halted the trial per protocol, and no further dose escalation was conducted. Follow-up cardiac evaluations revealed no structural or functional abnormalities in the affected subjects, and the relationship between JDTic and the cardiac events remains circumstantial but was judged sufficient to preclude further human testing of this specific compound. Development was terminated; subsequent KOR antagonist programs (aticaprant, LY2795050, navacaprant) have focused on short-acting compounds that do not activate JNK signaling.

This monograph reviews the chemistry, stereochemistry, and synthesis of JDTic; the molecular pharmacology including crystal structure-informed binding analysis; the JNK1-mediated mechanism of ultra-long duration; the comprehensive preclinical pharmacology across addiction, depression, anxiety, and pain models; the Phase 1 clinical experience and its safety implications; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety signal; and a structured comparative assessment of five KOR antagonists (norbinaltorphimine, 5-prime-guanidinonaltrindole, aticaprant, LY2795050, navacaprant) against JDTic on five competency standards. The compound is not approved by any regulatory authority for human use. It is supplied exclusively as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.